- Home
- SBR vs OLMA Comparison
SBR vs OLMA Comparison
Compare SBR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBR | OLMA |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 949.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBR | OLMA |
|---|---|---|
| Price | $73.87 | $7.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $36.50 |
| AVG Volume (30 Days) | 24.1K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | ★ 6.20% | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.31 | $6.65 |
| 52 Week High | $79.86 | $36.26 |
Technical Indicators
Market Signals| Indicator | SBR | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 19.25 |
| Support Level | $72.58 | N/A |
| Resistance Level | $76.59 | $11.27 |
| Average True Range (ATR) | 1.18 | 0.42 |
| MACD | 0.31 | -0.08 |
| Stochastic Oscillator | 100.00 | 2.25 |
Price Performance
Historical ComparisonAbout SBR Sabine Royalty Trust
Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.